Related Experiment Video
Updated: Jun 26, 2026
19:57
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Pediatric pharmacotherapy issues in Africa
1Department of Therapeutics and Medicines Management, Nelson R. Mandela School of Medicine, Durban, South Africa. graya1@ukzn.ac.za
Paediatric Drugs
|January 9, 2009
Summary
Pediatric pharmacotherapy in Africa faces significant hurdles including cost, disease burden, and lack of child-specific medicines. Initiatives like the WHO Essential Medicines List for Children aim to improve access to vital pediatric medications.
Area of Science:
- Global Health
- Pharmacology
- Pediatrics
Background:
- Pediatric pharmacotherapy in Africa is hindered by multifaceted challenges, impacting children's access to essential medicines.
- Key issues include financial constraints, high disease prevalence, workforce shortages, and a lack of pediatric-specific drug formulations.
Purpose of the Study:
- To highlight the critical barriers to effective pediatric pharmacotherapy in African healthcare systems.
- To underscore the global imperative of improving medicine access for children in resource-limited settings.
Main Methods:
- This study is a review of existing literature and initiatives focused on pediatric pharmacotherapy in Africa.
- It synthesizes information on challenges and potential solutions, referencing global health priorities and campaigns.
Main Results:
- Significant barriers identified include medicine affordability, sustainable healthcare financing, disease burden, human resource limitations, and inadequate child-friendly dosage forms.
- The lack of appropriate formulations particularly affects ambulatory pediatric care.
Conclusions:
- Improving pediatric pharmacotherapy in Africa requires addressing systemic issues alongside specific interventions.
- Global efforts, such as the WHO Essential Medicines List for Children and targeted campaigns, offer promising pathways to enhance medicine access for children.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...